MedTrace Logo

Role of Inflammasome in Platelet Activation in Sickle Cell Disease Patient

NCT06986837 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 92

Last updated 2025-05-23

No results posted yet for this study

Summary

Sickle cell disease is characterized by chronic hemolytic anemia, painful crisis called vaso-occlusive crisis and chronic inflammation. Activated platelets of Sickle cell disease patients participated to both chronic inflammation and painful vaso-occlusive crisis .

The main aim of this study is to characterize the contribution of Nucleotide-binding domain Leucine Rich repeat containing Protein 3 inflammasome in platelets' activation in Sickle cell disease and to connect platelet activation, inflammation and sickle cell disease complication.

Conditions

Sponsors & Collaborators

  • Centre Hospitalier Universitaire de la Guadeloupe

    lead OTHER

Principal Investigators

  • veronique Baccini, MD PhD · CHU de la Guadeloupe

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-10-14
Primary Completion
2023-02-05
Completion
2024-04-20

Countries

  • Guadeloupe

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06986837 on ClinicalTrials.gov